Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

The AI race between OpenAI and Google is heating up with the release of GPT-5.2. How does it compare to Gemini 3? Credit: Avishek Das/SOPA Images/LightRocket via Getty Images OpenAI's latest AI model ...

Jake Paul and Anthony Joshua are mere hours away from their much-anticipated boxing fight in Miami. Win or lose, both will walk away much richer. The Daily Mail reported in November that the purse for ...

First Federal Bank stands out for its exceptionally low interest rates and its emphasis on government loans. Most likely to appeal to borrowers shopping for low rates and fees. Strong experience in ...

The megalithic site of Gunung Padang in the highlands of western Java was constructed some 2,000 years ago over the course of several generations. Similar stone monuments are found across the ...

Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. The market approach is a method for determining the value of an ...

Apple's latest phone has a lot in common with the previous model, but there are notable improvements to the camera, display and battery. Is it worth the upgrade? Abrar's interests include phones, ...

The Federal Reserve wrapped up 2025 with three rate cuts that brought the federal funds rate down to a range between 3.5% and 3.75%. That shift is rippling through the banking system, but not at the ...